SurGenTec has received FDA clearance for its ION-L lumbar facet fixation system for patients with degenerative disc disease (DDD) affecting the L3 to S1 levels who have not responded to conservative treatment.
Designed for posterior lumbar procedures, ION-L aims to provide a less invasive alternative for facet joint fixation by reducing surgical exposure while supporting spinal fusion. The implant features a zero-profile design, bone graft integration technology, and mechanisms intended to improve stability and reduce implant migration.
Related: UNEEG Medical announces FDA 510(k) clearance for UNEEG EpiSight System
The company has now made ION-L commercially available as an addition to its spine technology portfolio.
SurGenTec CEO Travis Greenhalgh said:
“With ION-L, we have demonstrated that surgeons can achieve the same clinical goals through a less invasive, facet-based approach.”
The clearance strengthens SurGenTec’s position in the spine market by expanding its range of minimally invasive fixation solutions.
